17 December 2025

GENinCode Plc

("GENinCode" or the "Company")

CARDIO inCode-Score® distribution with Sohin Genetics, Mexico

Commercial agreement to distribute CARDIO inCode-Score®

for the genetic risk prediction and prevention of coronary heart disease

GENinCode Plc (AIM: GENI), the Oxford based predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk assessment of ovarian cancer, announces today a collaboration with Sohin Genetics, Mexico to distribute the CARDIO inCode-Score® Polygenic Risk Score ("PRS") test for the prevention of coronary heart disease ("CHD" or "heart disease").

This announcement follows the recent collaboration between GENinCode and "AMPAC" (Mexican Association for the prevention of Atherosclerosis) dedicated to research, education and promotion of healthy lifetstyles to combat atherosclerosis and heart disease in Mexico.

Sohin Genetics provide integrated healthcare services, especially in diagnostics, to deliver precision medicine access across their network of hospitals and clinics. Sohin Genetics will commercially promote and market CARDIO inCode-Score in the Mexican market including training, sample handling and ordering via the GENinCode 'SITAB' international reporting system. Mexico has a population of over 130 million with an estimated cardiovascular disease market of USD$ 4.3 billion with coronary heart disease the leading cause of death.    

CARDIO inCode-Score® (PRS)

CARDIO inCode-Score is a clinically validated, commercially available polygenic risk score (PRS) based on DNA extracted from a simple saliva or blood sample. The extracted DNA is scored to identify an individual's inherited genetic risk of heart disease thereby enabling prevention through lifestyle change and/or therapeutic treatment. The test has been designed and optimized for population-based risk prediction and primary prevention of heart disease and is being made available at affordable pricing to international healthcare systems.

By integrating CARDIO inCode-Score® into existing clinical pathways, healthcare providers can more accurately identify individuals at heightened 'lifetime risk' of heart disease and personalise treatment and prevention strategies. This preventive approach reduces the incidence of severe cardiovascular events, such as heart attacks and strokes, and mitigates the economic costs associated with long-term heart disease care. It represents a significant step to improving public health outcomes and particularly in addressing the global burden of cardiovascular disease.

Matthew Walls, GENinCode Chief Executive Officer said; "We are delighted to announce this latest distribution agreement with Sohin Genetics to sell CARDIO inCode-Score in Mexico. The collaboration will extend our reach into this growing cardiovascular disease market and allow us to consider other tests for distribution in the region."

For more information visit www.genincode.com

Enquiries:

Notes for editors

Coronary Heart Disease

Coronary Heart Disease ("CHD"), is the leading cause of death globally and is responsible for approx. 9 million deaths annually and estimated to affect over 250 million people suffering with symptoms of CHD¹. In the UK, it is the most common form of death and disability, with approximately 2.3 million people living with the condition².  

CHD occurs when the coronary arteries, which supply blood to the heart, become narrowed by build-up of fatty materials (cholesterol and other lipids) which give rise to what is commonly known as atherosclerosis or heart disease. Atherosclerosis restricts blood flow to the heart causing symptoms like angina (chest pain) with increasing atherosclerosis burden giving rise to heart attack (or ischemic stroke) if the artery becomes completely blocked by a blood clot.    

^1.  World Health Organisation - www.who.int - The leading causes of death

^2.  British Heart Foundation - www.bhf.org.uk - Statistics